Radiopharmaceuticals for prostate cancer to go nuclear with $6.3 bn in sales by 2030
Express Pharma
SEPTEMBER 18, 2024
billion in sales by 2030, according to GlobalData. billion by 2030, far outshining Xofigo. Pluvicto is indicated for metastatic CRPC (mCRPC) patients previously treated with ADT and taxane chemotherapy. billion by 2030. bn in sales by 2030 appeared first on Express Pharma.
Let's personalize your content